Business Context and Reporting Period
This Form 8-K Current Report, dated March 14, 2025, pertains to Akari Therapeutics Plc (Nasdaq: AKTX). The filing discloses significant changes to the Company's executive leadership, specifically the appointment of a new President and Chief Executive Officer (CEO) and the departure of the incumbent CEO.
Key Financial Metrics and Compensation
The filing does not contain financial performance data such as revenue, profit, cash flow, or debt levels. The primary financial disclosures relate to the compensation package for the new CEO, Mr. Abizer Gaslightwala:
- Base Salary: $475,000 annually.
- Annual Cash Bonus: Target of 50% of Base Salary, contingent on performance goals.
- Stock Options:
- 1,100,000 ADS (equivalent to 2,200,000,000 Ordinary Shares) with a four-year vesting schedule (25% at 12 months, remainder monthly).
- 600,000 ADS (equivalent to 1,200,000,000 Ordinary Shares) as a Performance Option.
- Severance (Without Cause/Good Reason): 12 months of Base Salary and target bonus, plus COBRA reimbursement.
- Severance (Change of Control): 1.5 times accrued obligations and immediate full acceleration of stock options.
Material Changes
The filing reports the following material changes to corporate governance and management:
- Appointment: Mr. Abizer Gaslightwala was appointed President and CEO, effective on or around April 21, 2025. He previously served as a director since December 16, 2024.
- Departure: Dr. Samir R. Patel will step down as President and CEO effective April 14, 2025. He will remain a member of the Board of Directors.
- Separation Terms: The specific severance terms for Dr. Patel are not yet finalized and are not disclosed in this filing.
Outlook, Risks, and Contingencies
Performance Milestones: The new CEO's Performance Option is contingent on meeting specific business milestones by December 31, 2025. If neither is met, the option will expire. The criteria are:
- Closing of a Qualified Financing of at least $15,000,000.
- Closing of an antibody drug conjugate focused license transaction with a minimum upfront payment of $10,000,000.
Risks and Contingencies: The filing notes that the terms of Dr. Patel's separation are still being finalized. The Company has indicated it will disclose required severance terms in a subsequent filing once finalized. No other specific risks or contingencies regarding the Company's operations are detailed in this report.
Investor Verification Checklist
- Verify the finalization and disclosure of Dr. Samir R. Patel's separation and severance terms in future filings.
- Monitor the Company's progress toward the $15 million financing or $10 million license deal required for the new CEO's performance equity to vest by December 31, 2025.
- Review the full text of the Employment Agreement (Exhibit 10.1) for detailed restrictive covenants and termination conditions.
- Confirm the exact start date of Mr. Gaslightwala's tenure, noted as "on or around April 21, 2025."